BAX vs. RPRX: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BAX and RPRX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | BAX | RPRX |
|---|---|---|
| Company Name | Baxter International Inc. | Royalty Pharma plc |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Equipment & Supplies | Pharmaceuticals |
| Market Capitalization | 11.68 billion USD | 21.01 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | October 27, 1981 | June 16, 2020 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of BAX and RPRX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BAX | RPRX |
|---|---|---|
| 5-Day Price Return | -2.07% | -1.29% |
| 13-Week Price Return | -23.68% | 0.42% |
| 26-Week Price Return | -27.43% | 13.31% |
| 52-Week Price Return | -36.40% | 30.65% |
| Month-to-Date Return | -0.09% | 2.10% |
| Year-to-Date Return | -21.98% | 41.20% |
| 10-Day Avg. Volume | 6.43M | 3.08M |
| 3-Month Avg. Volume | 6.43M | 4.00M |
| 3-Month Volatility | 53.69% | 20.81% |
| Beta | 0.62 | 0.46 |
Profitability
Return on Equity (TTM)
BAX
-2.12%
Health Care Equipment & Supplies Industry
- Max
- 29.93%
- Q3
- 16.99%
- Median
- 9.28%
- Q1
- 5.10%
- Min
- -12.52%
BAX has a negative Return on Equity of -2.12%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
RPRX
15.20%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
RPRX’s Return on Equity of 15.20% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
BAX
-1.42%
Health Care Equipment & Supplies Industry
- Max
- 24.41%
- Q3
- 13.71%
- Median
- 10.08%
- Q1
- 5.96%
- Min
- -5.58%
BAX has a negative Net Profit Margin of -1.42%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
RPRX
44.28%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
RPRX’s Net Profit Margin of 44.28% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
Operating Profit Margin (TTM)
BAX
-0.28%
Health Care Equipment & Supplies Industry
- Max
- 31.09%
- Q3
- 18.11%
- Median
- 15.07%
- Q1
- 8.48%
- Min
- -0.28%
BAX has a negative Operating Profit Margin of -0.28%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
RPRX
79.84%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
RPRX’s Operating Profit Margin of 79.84% is exceptionally high, placing it well above the typical range for the Pharmaceuticals industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.
Profitability at a Glance
| Symbol | BAX | RPRX |
|---|---|---|
| Return on Equity (TTM) | -2.12% | 15.20% |
| Return on Assets (TTM) | -0.65% | 5.66% |
| Net Profit Margin (TTM) | -1.42% | 44.28% |
| Operating Profit Margin (TTM) | -0.28% | 79.84% |
| Gross Profit Margin (TTM) | 36.01% | -- |
Financial Strength
Current Ratio (MRQ)
BAX
2.30
Health Care Equipment & Supplies Industry
- Max
- 5.19
- Q3
- 3.00
- Median
- 2.13
- Q1
- 1.44
- Min
- 0.86
BAX’s Current Ratio of 2.30 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.
RPRX
1.26
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
RPRX’s Current Ratio of 1.26 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
BAX
1.30
Health Care Equipment & Supplies Industry
- Max
- 1.61
- Q3
- 0.76
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
BAX’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 1.30. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
RPRX
1.26
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
RPRX’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 1.26. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
BAX
0.20
Health Care Equipment & Supplies Industry
- Max
- 56.35
- Q3
- 25.56
- Median
- 9.60
- Q1
- 3.78
- Min
- -26.49
BAX’s Interest Coverage Ratio of 0.20 is a critical concern. A value below 1.0 means operating earnings are insufficient to cover interest expenses, indicating severe financial strain and high default risk.
RPRX
4.70
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
RPRX’s Interest Coverage Ratio of 4.70 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | BAX | RPRX |
|---|---|---|
| Current Ratio (MRQ) | 2.30 | 1.26 |
| Quick Ratio (MRQ) | 1.20 | 1.26 |
| Debt-to-Equity Ratio (MRQ) | 1.30 | 1.26 |
| Interest Coverage Ratio (TTM) | 0.20 | 4.70 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BAX
3.99%
Health Care Equipment & Supplies Industry
- Max
- 4.15%
- Q3
- 1.76%
- Median
- 0.79%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 3.99%, BAX offers a more attractive income stream than most of its peers in the Health Care Equipment & Supplies industry, signaling a strong commitment to shareholder returns.
RPRX
1.79%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
RPRX’s Dividend Yield of 1.79% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
BAX
90.20%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 66.60%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
BAX’s Dividend Payout Ratio of 90.20% is in the upper quartile for the Health Care Equipment & Supplies industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
RPRX
36.87%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
RPRX’s Dividend Payout Ratio of 36.87% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | BAX | RPRX |
|---|---|---|
| Dividend Yield (TTM) | 3.99% | 1.79% |
| Dividend Payout Ratio (TTM) | 90.20% | 36.87% |
Valuation
Price-to-Earnings Ratio (TTM)
BAX
--
Health Care Equipment & Supplies Industry
- Max
- 67.29
- Q3
- 47.01
- Median
- 30.94
- Q1
- 23.91
- Min
- 10.79
P/E Ratio data for BAX is currently unavailable.
RPRX
20.56
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
RPRX’s P/E Ratio of 20.56 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
BAX
1.08
Health Care Equipment & Supplies Industry
- Max
- 9.49
- Q3
- 5.41
- Median
- 2.86
- Q1
- 2.07
- Min
- 0.74
In the lower quartile for the Health Care Equipment & Supplies industry, BAX’s P/S Ratio of 1.08 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
RPRX
9.11
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
With a P/S Ratio of 9.11, RPRX trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
BAX
2.12
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 6.56
- Median
- 3.53
- Q1
- 2.36
- Min
- 0.71
BAX’s P/B Ratio of 2.12 is in the lower quartile for the Health Care Equipment & Supplies industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
RPRX
3.19
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
RPRX’s P/B Ratio of 3.19 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | BAX | RPRX |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 20.56 |
| Price-to-Sales Ratio (TTM) | 1.08 | 9.11 |
| Price-to-Book Ratio (MRQ) | 2.12 | 3.19 |
| Price-to-Free Cash Flow Ratio (TTM) | 17.69 | 17.43 |